Maccura Biotechnology released its 2026 interim report on July 31, 2026. The company's total operating revenue was 1.034 billion yuan, down 3.82% from the same period last year. Net profit attributable to the parent was 34.257 million yuan, and net cash flow from operating activities was 259 million yuan. The company's latest asset-liability ratio was 18.99%, gross margin was 57.29%, ROE was 0.54%, and diluted earnings per share was 0.06 yuan.
Maccura Biotechnology Co LtdRevenue declined 3.82% YoY and net profit attributable to parent was only 34.257 million yuan, indicating weak financial performance.